180 related articles for article (PubMed ID: 31873846)
1. Reconstitution of NK cells expressing KIR3DL1 is associated with reduced NK cell activity and relapse of CML after allogeneic hematopoietic stem cell transplantation.
Ureshino H; Shindo T; Sano H; Kubota Y; Ando T; Kidoguchi K; Kusaba K; Itamura H; Kojima H; Kusunoki Y; Miyazaki Y; Kojima K; Tanaka H; Saji H; Oshima K; Kimura S
Int J Hematol; 2020 May; 111(5):733-738. PubMed ID: 31873846
[TBL] [Abstract][Full Text] [Related]
2. KIR3DL1 Allotype-Dependent Modulation of NK Cell Immunity against Chronic Myeloid Leukemia.
Izumi K; Shindo T; Ngo HT; Nakayama-Hosoya K; Akahane K; Tamai M; Nguyen TTT; Kawana-Tachikawa A; Inukai T; Takaori-Kondo A
Immunohorizons; 2021 Aug; 5(8):687-702. PubMed ID: 34433624
[TBL] [Abstract][Full Text] [Related]
3. KIR3DL1/HLA-B Subtypes Govern Acute Myelogenous Leukemia Relapse After Hematopoietic Cell Transplantation.
Boudreau JE; Giglio F; Gooley TA; Stevenson PA; Le Luduec JB; Shaffer BC; Rajalingam R; Hou L; Hurley CK; Noreen H; Reed EF; Yu N; Vierra-Green C; Haagenson M; Malkki M; Petersdorf EW; Spellman S; Hsu KC
J Clin Oncol; 2017 Jul; 35(20):2268-2278. PubMed ID: 28520526
[TBL] [Abstract][Full Text] [Related]
4. Allelic Polymorphisms of
Ureshino H; Shindo T; Kojima H; Kusunoki Y; Miyazaki Y; Tanaka H; Saji H; Kawaguchi A; Kimura S
Cancer Immunol Res; 2018 Jun; 6(6):745-754. PubMed ID: 29695383
[TBL] [Abstract][Full Text] [Related]
5. Donor KIR3DL1/3DS1 gene and recipient Bw4 KIR ligand as prognostic markers for outcome in unrelated hematopoietic stem cell transplantation.
Gagne K; Busson M; Bignon JD; Balère-Appert ML; Loiseau P; Dormoy A; Dubois V; Perrier P; Jollet I; Bois M; Masson D; Moine A; Absi L; Blaise D; Charron D; Raffoux C;
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1366-75. PubMed ID: 19822295
[TBL] [Abstract][Full Text] [Related]
6. Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation.
Sahin U; Dalva K; Gungor F; Ustun C; Beksac M
Ann Hematol; 2018 Jun; 97(6):1027-1039. PubMed ID: 29549412
[TBL] [Abstract][Full Text] [Related]
7. Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation.
Shilling HG; McQueen KL; Cheng NW; Shizuru JA; Negrin RS; Parham P
Blood; 2003 May; 101(9):3730-40. PubMed ID: 12511415
[TBL] [Abstract][Full Text] [Related]
8. Molecular relapse monitoring reveals the domination of impaired NK cell education over impaired inhibition in missing KIR-ligand recognition in patients after unrelated hematopoietic stem cell transplantation for malignant diseases.
Nowak J; Witkowska A; Rogatko-Koroś M; Malinowska A; Graczyk-Pol E; Nestorowicz-Kałużna K; Flaga A; Szlendak U; Wnorowska A; Gawron A
HLA; 2024 Feb; 103(2):e15364. PubMed ID: 38312022
[TBL] [Abstract][Full Text] [Related]
9. Allelic polymorphisms of
Shindo T; Ureshino H; Kojima H; Tanaka H; Kimura S
Immunol Med; 2021 Jun; 44(2):61-68. PubMed ID: 32715973
[TBL] [Abstract][Full Text] [Related]
10. Distinct graft-versus-leukemic stem cell effects of early or delayed donor leukocyte infusions in a mouse chronic myeloid leukemia model.
Lu YF; Gavrilescu LC; Betancur M; Lazarides K; Klingemann H; Van Etten RA
Blood; 2012 Jan; 119(1):273-84. PubMed ID: 22072555
[TBL] [Abstract][Full Text] [Related]
11. Donor T cells administered over HLA class II barriers mediate antitumor immunity without broad off-target toxicity in a NOD/scid mouse model of acute leukemia.
Stevanović S; Nijmeijer BA; van Schie ML; Salvatori DC; Maas S; Griffioen M; Falkenburg JH
Biol Blood Marrow Transplant; 2013 Jun; 19(6):867-75. PubMed ID: 23500532
[TBL] [Abstract][Full Text] [Related]
12. How important is NK alloreactivity and KIR in allogeneic transplantation?
Shaffer BC; Hsu KC
Best Pract Res Clin Haematol; 2016 Dec; 29(4):351-358. PubMed ID: 27890259
[TBL] [Abstract][Full Text] [Related]
13. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
[TBL] [Abstract][Full Text] [Related]
14. The BCR/ABL transgene causes abnormal NK cell differentiation and can be found in circulating NK cells of advanced phase chronic myelogenous leukemia patients.
Nakajima H; Zhao R; Lund TC; Ward J; Dolan M; Hirsch B; Miller JS
J Immunol; 2002 Jan; 168(2):643-50. PubMed ID: 11777957
[TBL] [Abstract][Full Text] [Related]
15. Hematopoietic stem cell transplantation: Improving alloreactive Bw4 donor selection by genotyping codon 86 of KIR3DL1/S1.
Alicata C; Pende D; Meazza R; Canevali P; Loiacono F; Bertaina A; Locatelli F; Nemat-Gorgani N; Guethlein LA; Parham P; Moretta L; Moretta A; Bottino C; Norman PJ; Falco M
Eur J Immunol; 2016 Jun; 46(6):1511-7. PubMed ID: 26990677
[TBL] [Abstract][Full Text] [Related]
16. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
17. Homozygous HLA-C1 is Associated with Reduced Risk of Relapse after HLA-Matched Transplantation in Patients with Myeloid Leukemia.
Arima N; Kanda J; Tanaka J; Yabe T; Morishima Y; Kim SW; Najima Y; Ozawa Y; Eto T; Kanamori H; Mori T; Kobayashi N; Kondo T; Nakamae H; Uchida N; Inoue M; Fukuda T; Ichinohe T; Atsuta Y; Kanda Y
Biol Blood Marrow Transplant; 2018 Apr; 24(4):717-725. PubMed ID: 29197675
[TBL] [Abstract][Full Text] [Related]
18. Patients with Philadelphia-positive leukemia with BCR-ABL kinase mutations before allogeneic transplantation predominantly relapse with the same mutation.
Egan DN; Beppu L; Radich JP
Biol Blood Marrow Transplant; 2015 Jan; 21(1):184-9. PubMed ID: 25300870
[TBL] [Abstract][Full Text] [Related]
19. Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib.
Yong AS; Keyvanfar K; Hensel N; Eniafe R; Savani BN; Berg M; Lundqvist A; Adams S; Sloand EM; Goldman JM; Childs R; Barrett AJ
Blood; 2009 Jan; 113(4):875-82. PubMed ID: 18922853
[TBL] [Abstract][Full Text] [Related]
20. Reconstitution of natural killer cell receptor repertoires after unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation: analyses of CD94:NKG2A and killer immunoglobulin-like receptor expression and their associations with clinical outcome.
Zhao XY; Huang XJ; Liu KY; Xu LP; Liu DH
Biol Blood Marrow Transplant; 2007 Jun; 13(6):734-44. PubMed ID: 17531784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
